FDA’s Advisory Committee Supports CTL019 in Pediatric, Young Adult Patients With B-Cell ALL

Today, the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) met to discuss the biologics license application (BLA) for the chimeric antigen receptor (CAR) T-cell therapy CTL019 (tisagenlecleucel) for the treatment of relapsed or refractory pediatric and young adult patients with B-cell acute lymphoblastic leukemia (ALL). The committee voted unanimously in favor of CTL019 for this indication. 

CTL019 is an adoptive immunocellular cancer therapy using autologous peripheral blood T cells that have been reprogrammed with a transgene encoding a CAR to identify and eliminate CD19-expressing malignant and nonmalignant cells. The efficacy and safety of CTL019 have been evaluated in 3 trials involving over 150 pediatric and young adult patients with relapsed/refractory B-cell ALL, with a maximum follow-up extending to 40.5 months. The data were summarized and submitted to the FDA in February 2017.

A final decision from the FDA is expected later this year. 

The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.


Advertisement

Advertisement



Advertisement

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.